UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009937
Receipt number R000011642
Scientific Title The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r)
Date of disclosure of the study information 2013/02/05
Last modified on 2013/02/07 18:19:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r)

Acronym

The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r)

Scientific Title

The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r)

Scientific Title:Acronym

The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r)

Region

Japan


Condition

Condition

Ulcerative colitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Comparing the efficacy of Asacolo with Pentasa.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

CAI score
EI score
Endoscopic examination( biopsy)
Blood test

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral administration of Asacolo 3600mg/day
or Pentasa 4000mg/day

Interventions/Control_2

Oral administration of Asacolo 3600mg/day
or Pentasa 4000mg/day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <

Age-upper limit

99 years-old >

Gender

Male and Female

Key inclusion criteria

The relapse UC patients with oral intake of Asacolol less than 3600mg/day or Pentasa less than 4000mg.
Agreement about this study
Over 16 years

Key exclusion criteria

Over daily ten times of diarhea
The patients who are considerd inapproval for this study by their outhospital doctors

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hidemi Goto

Organization

NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE

Division name

Gastroenterology and Hepatology

Zip code


Address

Tsurumai 65 Showaku Nagoya city Aichi prefecture Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Gastroenterology and Hepatology

Division name

Gastroenterology1

Zip code


Address


TEL


Homepage URL


Email

mmatusita@med.nagoya-u.ac.jp


Sponsor or person

Institute

NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE

Institute

Department

Personal name



Funding Source

Organization

NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 02 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2012 Year 02 Month 05 Day

Date of IRB


Anticipated trial start date

2012 Year 03 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 02 Month 03 Day

Last modified on

2013 Year 02 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011642


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name